Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2017
At a glance
- Drugs CYD TDV (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Dengue; Human papillomavirus infections
- Focus Pharmacodynamics
- Sponsors sanofi pasteur
- 28 Jun 2017 Planned End Date changed from 1 Oct 2018 to 14 Feb 2019.
- 28 Jun 2017 Planned primary completion date changed from 1 Oct 2018 to 14 Feb 2019.
- 19 Dec 2016 New trial record